



Orbital Considerations in Sinonasal Malignancy

Mindy R. Rabinowitz, MD

Grand Rounds

June 8, 2016

Outline

- Anatomy
- Epidemiology
- Presentation
- Pathology
- Orbital Invasion
- Evaluation
- Management
- Sequela
- Disease-specific management
- Research

Outline

- **Anatomy**

- **Sinus/Orbit**

- Epidemiology
 - Presentation
 - Pathology
 - Orbital Invasion
 - Evaluation
 - Management
 - Sequela
 - Disease-specific management
 - Research

Anatomy

{ Sinonasal }

Superior
Turbinate


Middle
Turbinate

Inferior
Turbinate

Hard Palate

Nasal Spine

Sphenoid




Anatomy

{ Sinonasal }

Lateral
Nasal
Sidewall



Medial
Wall of
Maxillary
Sinus



Anatomy

{ Sinonasal }


Superior
Turbinates



Middle
Turbinates



Inferior
Turbinates




Anatomy

{ Sinonasal }

Medial Orbital
Wall/
Lamina
Papyracea

Ethmoid
Air Cells



Anatomy

Sinonasal

Lamina
Papyracea
a



Anatomy


Orbit

Lacrimal
Fossa



Anatomy


Orbit



Anatomy

[Orbit]


Maxillary



Anatomy

[Orbit]


Zygomamatic



Anatomy

Orbit


Frontal



Anatomy

Orbit


Sphenoid



Anatomy

Orbit


Lacrimal



Anatomy

Orbit


Ethmoid



Anatomy

Orbit

Palatine




Anatomy

[Orbit]




Anatomy

Orbit




Anatomy

Orbit



Anatomy

Peri-orbita




Anatomy

[Orbit]

Periorbita

Lateral
canthal
tendon




Anatomy

Orbit

Septations


Periorbital Fat



Anatomy

[Orbit]

Fat tracks
back to
orbital apex



Outline

- Anatomy

- **Epidemiology**

- Presentation

- Pathology

- Orbital Invasion

- Evaluation

- Management

- Sequela

- Disease-specific management

- Research

Epidemiology

Prevalence

- 1% of all malignancies
- ~5% of H&N malignancies

Incidence

- Europeans: 1: 100,000
- Asians: 3: 100,000

SEER Data

- 6730 Non-lymphoreticular malignancies
- 1973-2006

Age

6th decade

Gender



Male (58%)

Race

White (82%) > Black > "Other"

Epidemiology


Rate of
Sinonasal



Gender

Epidemiology

Race



Outline

- Anatomy
- Epidemiology

- **Presentation**

- Pathology
- Orbital Invasion
- Evaluation
- Management
- Sequela
- Disease-specific management
- Research

Presentation


Local

- Nasal Obstruction
- Bleeding
- Discharge
- Hyposmia
- Unilateral ETD
- Epistaxis

Regional

- LAD
- **Orbital Changes**
- Diplopia
- Epiphora
- CN Dysfunction

- Exophthalmos
- Headache
- Facial Swelling
- Numbness



Outline

- Anatomy
- Epidemiology
- Presentation

• Pathology

- Orbital Invasion
- Evaluation
- Management
- Sequela
- Disease-specific management
- Research

Sinonasal Malignancies

Epithelial Epidermoid

- Squamous cell ca
- Lymphoepithelial ca
- Carcinomas of lacrimal sac

Mesenchymal

- Solitary Fibrous Tumors
- Liposarcoma
- Fibrosarcoma
- Malignant Fibrous Histiocytoma
- Synovial Sarcoma
- Alveolar Soft Part Sarcoma

Bone

- Osteosarcoma

Lymphoreticular

- Lymphoma
- Extramedullary Plasmacytoma

Cartilage

- Chondrosarcoma

Salivary

- Adenocarcinoma
- Adenoid Cystic Ca
- Mucoepidermoid Ca
- Acinic cell ca
- Carcinoma ex-pleomorphic adenoma

Vasoform

- Angiosarcoma

Muscle

- Rhabdomyosarcoma
- Leiomyosarcoma

Neuroectodermal

- Malignant Peripheral Nerve Sheath Tumor
- Meningioma
- Neuroendocrine Carcinoma
- SNUC
- Ewings
- Olfactory Neuroblastoma
- Mucosal Melanoma

Metastases

Sinonasal Malignancies

Epithelial Epidermoid

- **Squamous cell ca**
- Lymphoepithelial ca
- Carcinomas of lacrimal sac

Mesenchymal

- Solitary Fibrous Tumors
- Liposarcoma
- Fibrosarcoma
- Malignant Fibrous Histiocytoma
- Synovial Sarcoma
- Alveolar Soft Part Sarcoma

Bone

- Osteosarcoma

Lymphoreticular

- Lymphoma
- Extramedullary Plasmacytoma

Cartilage

- Chondrosarcoma

Salivary

- **Adenocarcinoma**
- **Adenoid Cystic Ca**
- Mucoepidermoid Ca
- Acinic cell ca
- Carcinoma ex-pleomorphic adenoma

Vasoform

- Angiosarcoma

Muscle

- **Rhabdomyosarcoma**
- Leiomyosarcoma

Neuroectodermal

- Malignant Peripheral Nerve Sheath Tumor
- Meningioma
- Neuroendocrine Carcinoma
- **SNUC**
- Ewing
- **Olfactory Neuroblastoma**
- **Mucosal Melanoma**

Metastases

Sinonasal Malignancies

Epithelial Epidermoid

- Squamous cell ca

Salivary

Squamous Cell Carcinoma

Lymphoproliferative

- Lymphoma
- Extramedullary Plasmacytoma

Cartilage


- Chondrosarcoma

- Neuroendocrine Carcinoma
- SNUC
- Ewings
- Olfactory Neuroblastoma
- Mucosal Melanoma

Metastases

Sinonasal Malignancies

SQUAMOUS CELL
CARCINOMA



80% Sinonasal Malignancies

60-70 years of age

M > F

Risk Factors....

- Nickel
- Chromium
- Bantu snuff
- Hydrocarbons
- Radium
- XRT
- IP
- Thorotrast
- Mustard Gas
- Cigarettes
- Wood
- EtOH
- Immunosup

5 year survival: 60%

Surgery, Chemo, XRT

Sinonasal Malignancies

Epithelial Epidermoid

- Squamous cell ca

Salivary

Adenocarcinoma

Lymphoproliferative

- Lymphoma
- Extramedullary Plasmacytoma

Cartilage


- Chondrosarcoma

- Neuroendocrine Carcinoma
- SNUC
- Ewings
- Olfactory Neuroblastoma
- Mucosal Melanoma

Metastases

Sinonasal Malignancies

ADENOCARCINOMA



Ethmoid Sinuses

Leather & Wood Workers

Advanced at Presentation:
50% cribiform erosion

Tx: Surgery → XRT



Sinonasal Malignancies

Epithelial Epidermoid

- Squamous cell ca

Salivary

Adenoid Cystic Carcinoma

Lymphoproliferative

- Lymphoma
- Extramedullary Plasmacytoma

Cartilage


- Chondrosarcoma

- Neuroendocrine Carcinoma
- SNUC
- Ewings
- Olfactory Neuroblastoma
- Mucosal Melanoma

Metastases

Sinonasal Malignancies

ADENOID CYSTIC CARCINOMA



- Most common salivary neoplasm
- Location:
 - Maxillary > N.C. > Sphenoid/Frontal
- Peri-neural spread
 - Extension → orbit & intracranial
 - Difficult to clear
- Treatment:
 - Surgical rxn
 - Adjuvant XRT
- 50% Distant Mets → **Lung, Brain, Bones**

Sinonasal Malignancies

Epithelial Epidermoid

- Squamous cell ca

Salivary

Rhabdomyosarcoma

Lymphoproliferative

- Lymphoma
- Extramedullary Plasmacytoma

Cartilage


- Chondrosarcoma

- Neuroendocrine Carcinoma
- SNUC
- Ewings
- Olfactory Neuroblastoma
- Mucosal Melanoma

Metastases


Sinonasal Malignancies

RHABDOMYOSARCOMA



Embryonal, → Children
Alveolar, → Adolescence
→ Adults

Pleomorphic
Adults: 2-5%
Children: 60% } 35% Head and Neck



Nasal Cavity, Nasopharynx, Sinuses

Adults: Ethmoids

Treatment: Surgery, Chemo/
XRT

Sinonasal Malignancies

Epithelial Epidermoid

- Squamous cell ca

Salivary

Sinonasal Undifferentiated Carcinoma (SNUC)

Lymphoproliferative

- Lymphoma
- Extramedullary Plasmacytoma

Cartilage

- Chondrosarcoma

- Neuroendocrine Carcinoma
- SNUC
- Ewings
- Olfactory Neuroblastoma
- Mucosal Melanoma

Metastases

Sinonasal Malignancies

SINONASAL UNDIFFERENTIATED CARCINOMA

Derived from Schneiderian epithelium

Mean age of dx: 6th decade

Aggressive neoplasms


- Advanced presentation
 - 20-30% Cervical LAD
- Metastatic disease

Rapid growth

- Site of origin?

Treatment Controversial:

- Chemo/XRT w/ surgical salvage
- Surgery → Chemo/XRT



Sinonasal Malignancies

Epithelial Epidermoid

- Squamous cell ca

Salivary

Olfactory Neuroblastoma

Lymphoproliferative

- Lymphoma
- Extramedullary Plasmacytoma

Cartilage


- Chondrosarcoma

- Neuroendocrine Carcinoma
- SNUC
- Ewings
- Olfactory Neuroblastoma
- Mucosal Melanoma

Metastases

Sinonasal Malignancies

OLFACTORY NEUROBLASTOMA



- Arise from olfactory neuroepithelium
- Bimodal
 - 2nd-3rd decade
 - 6-7th decade
- Cross cribriform
→ Intracranially
- Treatment:
 - Craniofacial rsxn ± XRT
- Long natural history
 - Locoregional recurrence
 - Up to 10 years
- Long term follow up necessary

Sinonasal Malignancies

Epithelial Epidermoid

- Squamous cell ca

Salivary

Mucosal Melanoma

Lymphoproliferative

- Lymphoma
- Extramedullary Plasmacytoma

Cartilage

- Chondrosarcoma

- Neuroendocrine Carcinoma
- SNUC
- Ewings
- Olfactory Neuroblastoma
- Mucosal Melanoma

Metastases

Sinonasal Malignancies

MUCOSAL
MELANOMA

~20% Head & Neck

~2-5% Sinonasal Cavity

Nasal Septum*

Turbinate → 80% Maxillary Sinus

Male > Female


5-7th Decade

Spread by local invasion

LN Metastasis → 6% of cases

Treatment:

- Surgery ± XRT
- Local Failure: 50%
- Mean Survival: ~2 years



Loevner, Sonners 2002
Raghavan, Phillips, 2007
Lung, Howard, Wei. 2014

Outline

- Anatomy
- Epidemiology
- Presentation
- Pathology

• Orbital Invasion

- Evaluation
- Management
- Sequela
- Disease-specific management
- Research

- Epidemiology
- Presentation
- Mechanism of Action
- Definition
- Prognosis

Orbital invasion by malignancies

Varies with:

- Site of origin
- Histology
- Tumor Aggressiveness

Diagnosed at advanced stage

Orbital Involvement:


- 60-80%: Maxillary & Ethmoid
- 30-50% Periorbital Involvement

Presentation

Ocular Symptoms

62% Ethmoidal Tumors


46% Nasal Cavity Tumors



Bleier, Lin. 2012
Loevner, Sonners. 2002
Essig, Newman, Levine. 2007
Suarez, Ferlito, Dpath et. al. 2007
Singh, Eskander, Huang, et.al. 2013

Mechanism of Action

All 4 sinuses surround the orbit...




Mechanism of Action

All 4 sinuses surround the orbit...



Mechanism of Action

All 4 sinuses surround the orbit...




Mechanism of Action

Opportunities for orbital extension

- Multiple foramina
- Perforating nerves/ vessels
- Thin bones
 - Lacrimal fossa
 - Lamina papyracea
- Periorbita



No natural
intra/extra-conal barriers




“Orbital Invasion”

Orbital wall erosion?

Periorbital Involvement?


Orbital Soft Tissues?



“Orbital Invasion”

Periorbita

- “True protector” of orbit
- Intact despite bone erosion
- Defines orbital invasion?
- Degree of invasion
 - Partial vs. Full thickness?



“Orbital Invasion”

Orbital Invasion- 35-75% of cases

Discordant definitions

McCary et al

- A: Adj to orbit, no wall
- B: Wall erosion, no globe displacement
- C: Wall erosion & infiltration, no periorbita
- D: Invades orbit & periorbita

Ianetti et al

- I: Wall erosion
- II: Orbital fat
- III: MR, globe, ON, palpebral skin

No Agreement

Poor Prognosis

Ganly et al 2005

334 pts CFR for ethmoid tumors

LACK of orbital invasion...

- Predict recurrence free, disease specific and overall survival
- DSS:
 - + Orbit: 41%
 - - Orbit: 75%

ORBITAL SOFT TISSUE INVOLVEMENT

- Independent factor influencing survival

INVASION LIMITED TO PERIORBITA

- Survival unchanged

Outline

- Anatomy
- Epidemiology
- Presentation
- Pathology
- Orbital Invasion

• Evaluation

- Management
 - Sequela
 - Disease-specific management
 - Research
- Imaging
 - Definitive

Imaging

- No symptoms \neq No invasion
- CT & MRI important!


Penetrate bony orbit; possibly periorbita

Erode bone only

Useful for distinguishing...

Directly abut the orbit w/o bone invasion

Orbital soft tissues



Imaging

CRITERIA

Eisen et.al. 2000

*Predict
Periorbital
Invasion*

Relationship to Periorbita

- Abutting
- Displacing
- Bowing

Interface: Tumor & Periorbita

- “nodular”
- “smooth”

Orbital Fat Invasion

- Stranding in extraconal fat

Extraocular Muscles

- Displaced
- Enlarged
- Abnl

intensity

Orbital Bone Integrity

Nasolacrimal Invasion

- Tumor in duct or sac

Conclusions

- No one criterion had accuracy >79%
- ≥ 6 criteria predicted orbital invasion w/ accuracy 72%.
- Adjacent to periorbita: most sensitive (90%), low specificity (29-44%)
- EOM enlargement: most specific (94%)
- Orbital Fat Involvement: specific, high PPV, but less sensitive

Imaging

CT

CT more accurate than
MRI

Strength of CT


- Evaluate bone, fat interface

Difficulty distinguishing tumor...

- Compresses vs. invades
periorbital

Ill defined hazy
density


Ethmoid
carcinoma



Imaging

CT

Erosion of
lateral nasal wall
and frontal sinus
floor




Thinning &
bowing
Medial orbital
wall

Imaging

MRI

Periorbita

Hypo
T1, T2



Invasion of the periorbita:

- Results in loss of signal

Imaging

MRI


Loss of fat signal

Abnormal
signal in fat

Normal
bright fat
on T1



Tumor Nodularity




Mass Effect of
Medial Rectus

Imaging

MRI

Tumor
Nodularity



Definitive Evaluation

The background of the slide features a glass of water with several ice cubes. A large, semi-transparent blue oval is centered over the image, containing the text 'Intra-operative frozen section'.

**Intra-operative frozen
section**

Outline


- Anatomy
- Epidemiology
- Presentation
- Pathology
- Orbital Invasion
- Evaluation

• Management

- Sequela
- Disease-specific management
- Research

- Controversy
- Surgery
- Radiation/Chemo

Management



Surgery

XRT

Chemo

Management


Surgery

- Exenteration
- Debulk

XRT

Chemo

Controversies



Orbital
Exenteration

1970

Orbital Preservation

2016

Points of
Contention

1. Oncological Safety of Orbital Preservation
2. Functional Outcome in Preserved Eyes.

Orbital Exenteration

Support for

Imola 2002

1. Involvement of the orbital apex
2. Non-resectable full-thickness invasion through periorbita into retrobulbar fat
3. Extension into the EOM
4. Invasion of the bulbar conjunctiva
5. Lid involvement beyond reasonable hope for reconstruction

- Study over 200 pts
- Local control rate:
 - 79% **with** exenteration
 - 14% **without** exenteration

Probably unwise to conclude
that the orbit can be spared in
all patients

Orbital Exenteration

Support for

Anderson (1996)

- 32% incidence of non-functional eye
- 58 patients- anterior CFR, orbit preservation, adjuvant XRT

“Strong consideration for orbital exent based on anticipated poor functional outcomes”

Rajapurkar (2013)

- 19 total/radical maxillectomy
 - 4/19- orbital floor + periorbita + Fat (orbit preserved)
 - $\frac{3}{4}$ - orbital + margins (despite XRT)
 - Recurred

If cant ensure complete negative orbital margins, exent may be safer oncologically

Orbital Exenteration

Support
Against

Contraindications

- Brain?
- Cavernous Sinus
- Carotid Artery
- Bilateral Optic n.
- Optic Chiasm

Psychosocial

- 27 patients → Orbital Preservation
 - All were glad eye was spared

The cosmetic, functional, and psychologic consequences of loss of an eye mandate that every effort should be made to preserve the eye as long as **oncologic safety is not compromised.**”

Orbital Exenteration

Support
Against

Reyes, mason, Solares, Bush, Carrau. 2015

Source	Indication for evisceration	5-year survival evisceration, %	5-year survival preservation, %
Wu et al ¹⁷	Invasion medial orbital wall ^a	27.3	34.8
Lund et al ¹⁹	Transgression of the periosteum ^b	29	26
Imola et al ²⁰	Orbital fat involvement, extraocular muscle invasion, orbital apex, or eyelid invasion ^c	46	53
Iannetti et al ¹⁸	Invasion of the medial rectus muscle, optic nerve, ocular bulb, or the skin overlying the eyelid ^c	62.2	63.5

No strong evidence favoring preservation vs. exenteration

Criticisms:

- Tumor histology not taken into account.
 - Effect may be limited to SCC, Adenoca
- Different indications for exenteration
- Preserved: not description of what resected

Orbital Exenteration

Bartisch

- “Starved” the day of the operation
- Held down by 2 assistants
- No anesthesia
- Pass needle & silk thread through globe
 - Exerting forward traction
- Cut attachments to eye with curved knife
- Bandage placed
 - Enriched with sulfured spelter and brandy



1583

Orbital Exenteration

Involves removal of the soft tissue contents of the orbit, including the globe.

Total:

- globe, eyelid, conjunctiva, orbital contents, periorbita


Extended:

- bony orbital walls, paranasal sinuses, \pm intracranial tissue


Subtotal:

- globe, conjunctiva, EOM


Orbital Exenteration




Orbicularis







Periosteum





Orbital Exenteration



Orbital Exenteration



Orbital Exenteration





Management

Surgery

XRT

Chemo



Management

Surgery

- Exenteration
- Debulking

XRT

Chemo

Orbital Preservation/ XRT

TABLE IV.
Patterns of Local Recurrence According to Primary Tumor Site in Patients Treated With Orbital Preservation versus Orbital Exenteration.

Histologic Subtype	Orbital Preservation (54)				Orbital Exenteration (12)	
	No.	Local Sinonasal Recurrence			No.	Local Recurrence
		-Orbital Disease	+Orbital Disease	Total		
SCCa	18	4	2	6 (11.1)*	6	2 (16.7)
SNUC	6	1	1	2 (3.7)	2	1 (8.3)
Adenomatous	10	2	1	3 (5.6)	3	1 (8.3)
Sarcoma	11	3	—	3 (5.6)	1	—
Other	9	2	—	2 (3.7)	—	—
TOTAL	54	12	4	16 (29.6)	12	4 (33.3)

-Orbital disease = local recurrence in the sinonasal cavity remote from the original site of orbital involvement.

+Orbital disease = local recurrence in the sinonasal cavity with involvement of the original orbital site.

*Values in parentheses are percentages.

Eye preservation could be attempted in any malignancy that invaded the orbital soft tissues with penetration through the periorbital fat provided that it could be easily and completely dissected away from the orbital fat.

No statistically significant difference in recurrence rates

Orbital Preservation/ XRT

Disease-free survival in patients with orbital invasion

	Orbital Preservation†	Exenteration‡	Significance (P)
Som et al. (1974)	—	3/27 (11%)	>.05
Perry et al. (1988)	1/2 (50%)	2/4 (50%)	
Xuexi et al. (1995)	8/23 (35%)	24/88 (27%)	
Carrau et al. (current study)	5/9 (56%)	6/12 (50%)	
Total	14/34 (41%)	35/131 (37%)	

No
difference in
survival

Local recurrence in patients with orbital invasion


	Orbital Preservation†	Exenteration‡	Significance (P)
Som et al. (1974)	—	22/27 (81%)	>.05
Perry et al. (1988)	1/2 (50%)	1/4 (25%)	
Xuexi et al. (1995)	2/23 (9%)	11/88 (13%)	
McCary et al. (1996)	1/5 (20%)	—	
Carrau et al. (current study)	0/11 (0%)	0/11 (0%)	
Total	4/56 (7%)	34/131 (26%)	

No difference
in local
recurrence

Preservation of the orbit, when the full thickness of periorbita is not invaded, does not downgrade outcome and therefore supports a trend toward orbital preservation.

Survival: Sinonasal Malignancy

5- Year Survival: Sinonasal Malignancy



Not specific to orbital invasion

Orbital Preservation/ XRT

University of Virginia Protocol (SNUC, Esthesio)


- Preop XRT
 - Effort to spare globe, lacrimal gland
- Chemo?
- Salvage surgery

- **33 patients: Orbital invasion**
 - Invaded bone & displaced periorbita
 - Grossly invaded the orbit & periorbita
- No eyes removed
- 5/33: Local recurrence
 - 1/5: in orbit

Pre-op XRT

- Reduce tumor size
- Tumor in orbit replaced by scar
 - Easily dissected from fat

Algorithm for Managing Orbit



Outline

- Anatomy
- Epidemiology
- Presentation
- Pathology
- Orbital Invasion
- Evaluation
- Management
- **Sequela**
 - Disease-specific management
 - Research


Sequela of Function

Points of Contention

Oncological Safety of Orbital Preservation

Functional Outcome in Preserved Eyes

Sequela of Function



Surgery
alone

radiation alone


Surgery &
radiation

Sequela of Function

Surgery alone


Imola, Schramm 2002

Functional **without** impairment



54%

Functional **with** impairment



37%

Non-Functional



9%

“Functional”
day-to-day use of the eye (VA, globe position, lacrimal integrity, etc..)

Most Common:

- Lack of adequate reconstruction
- Diplopia

Sequela of Function

radiation alone

Loss of Ocular
Function

- Ipsilateral Orbit: 79%
- Contralateral Orbit: 5%

Loss of Ocular Function

Sequela of Function

radiation alone

Overall Incidence of Functional Ocular Sequelae and the Influence of Radiation Therapy in the Group of Patients Treated With Orbital Preservation.

Ocular Sequelae	Occurrence in Orbital Preservation Group		
	Overall (54)	Radiation Therapy (39)	No Radiation Therapy (15)
Ectropion	11 (20)*	9 (23)	2 (13)
Blepharitis/conjunctivitis	18 (33)	15 (38)	3 (20)
Corneal exposure keratopathy	6 (11)	5 (13)	1 (7)
Epiphora	7 (13)	2 (5)	5 (33)
Dryness	5 (9)	5 (12.8)	
Optic atrophy	2 (4)	2 (5)	
Cataract formation	4 (8)	4 (10)	

*Values in parentheses are percentages.

Sequela of Function

Surgery & radiation

McCary 1996

- 29/ 33-
 - Pre-op XRT
 - Rrxn of periorbita
- 55%: No ophthalmic problems
- 45%:
 - Exposure Keratitis (6 pts)
 - Motility Disturbance (6 pts)
 - 5 pts: transient or asymptomatic
 - Cataracts
 - Ectropion
 - Dsytopia
 - Enophthalmos

Bleier 2012, Suarez 2008

- Increased risk of:
 - Otpic atrophy
 - Cataracts
 - Excessive dryness
 - Ectropion

Outline

- Anatomy
- Epidemiology
- Presentation
- Pathology
- Orbital Invasion
- Evaluation
- Management
- Sequela
- **Disease-specific management**
- Research

Outcomes...

Sparing the soft tissues of the orbit when the periorbita have not been deeply transgressed by tumor generally does not appear to adversely affect local control.

Outcomes...

Confounding factors...

Selection Bias

- More advanced tumors → Exenteration
- More favorable tumors → Preservation

Tumor Histology

- Plays significant role in outcome

Local Recurrence

Histologic Subtype

Histologic Subtype	Orbital Preservation (54)				Orbital Exenteration (12)	
	No.	Local Sinonasal Recurrence			No.	Local Recurrence
		-Orbital Disease	+Orbital Disease	Total		
SCCa	18	4	2	6 (11.1)*	6	2 (16.7)
SNUC	6	1	1	2 (3.7)	2	1 (8.3)
Adenomatous	10	2	1	3 (5.6)	3	1 (3.3)
Sarcoma	11	3	—	3 (5.6)	—	—
Other	9	2	—	2 (3.7)	—	—
TOTAL	54	12	4	16 (29.6)	12	4 (33.3)

Not Statistically Significant

-Orbital disease = local recurrence in the sinonasal cavity remote from the original site of orbital involvement.

+Orbital disease = local recurrence in the sinonasal cavity with involvement of the original orbital site.

*Values in parentheses are percentages.

Low numbers of each histology

Conclusions...

Periorbita not deeply transgressed

✧ Does not affect local control/survival

✧ Preserve orbit

Outcomes less clear when fat is invaded

Surgery/XRT- Preserved eye with variable level of function

Tumor histology/behavior matters

Outline

- Anatomy
- Epidemiology
- Presentation
- Pathology
- Orbital Invasion
- Evaluation
- Management
- Sequela
- Disease-specific management

• **Research**

Jefferson Data

Goals

...

1. Evaluate recurrence and survival rates based on tumor histology for orbital preservation vs. exenteration
2. Stratify based on extent of tumor resection & degree of invasion
 - Attention to orbital fat

Jefferson Data

Data

Inv pap w/ SCC	6
SCC	15
BCC	2
Melanoma	3
Esthesio	5
Poorly diff/undiff	13
Spindle Cell	2
SNUC	2
ACC	2

MucoEp	1
Hemangioperi	1
AdenoCA	5
Sarcoma	1
Alveolar Rhabdo	2
Sebaceous CA	1
Leiomyosarcoma	1
Myoepithelioma	1
Plasmacytoma	1

Acknowledgements

Otolaryngology

Marc Rosen

Gurston Nyquist

Oculoplastics

Michael Rabinowitz

Medical Students

Kurien Gil

Varun Patel

Krystal Park

Outline

- References

- Reyes C, Mason E, Solares CA, Bush C, Carrau R. To preserve or not to preserve the orbit in paranasal sinus neoplasms: a meta-analysis. *J Neurol Surg B Skull Base*. 2015 Mar;76(2):122-8.
- Stern SJ, Goepfert H, Clayman G, Byers R, Wolf P. Orbital preservation in maxillectomy. *Otolaryngol Head Neck Surg*. 1993 Jul;109(1):111-5
- Suárez C, Ferlito A, Lund VJ, Silver CE, Fagan JJ, Rodrigo JP, Llorente JL, Cantù G, Politi M, Wei WI, Rinaldo A. Management of the orbit in malignant sinonasal tumors. *Head Neck*. 2008 Feb;30(2):242-50.
- Imola MJ, Schramm VL Jr. Orbital preservation in surgical management of sinonasal malignancy. *Laryngoscope*. 2002 Aug;112(8 Pt 1):1357-65.
- Bleier, BS, Derrick TL. "Surgical Debate: Orbital Exenteration". In *Sinonasal Tumors* by Chiu AG, Ramakrishnan VR, Suh JD. Jaypee Brothers Medical Publishers. 2012.
- Turner JH, Reh DD. Incidence and survival in patients with sinonasal cancer: a historical analysis of population-based data. *Head Neck*. 2012 Jun;34(6):877-85.
- Harvey RJ, Dalgorf DM. Chapter 10: Sinonasal malignancies. *Am J Rhinol Allergy*. 2013 May-Jun;27 Suppl 1:S35-8.
- McCary WS, Levine PA. Management of the eye in the treatment of sinonasal cancers. *Otolaryngol Clin North Am*. 1995 Dec;28(6):1231-8. Review.
- Manjunath L, Drousseau T, Batra PS. Prognostic value of surgical margins during endoscopic resection of paranasal sinus malignancy. *Int Forum Allergy Rhinol*. 2015 May;5(5):454-9.
- Curtin HD, Rabinov JD. Extension to the orbit from paraorbital disease. The sinuses. *Radiol Clin North Am*. 1998 Nov;36(6):1201-13
- Raghavan P, Phillips CD. Magnetic resonance imaging of sinonasal malignancies. *Top Magn Reson Imaging*. 2007 Aug;18(4):259-67.
- Loevner LA, Sonners AI. Imaging of neoplasms of the paranasal sinuses. *Neuroimaging Clin N Am*. 2004 Nov;14(4):625-46.
- Rajapurkar M, Thankappan K, Sampathirao LM, Kuriakose MA, Iyer S. Oncologic and functional outcome of the preserved eye in malignant sinonasal tumors. *Head Neck*. 2013 Oct;35(10):1379-84. doi: 10.1002/hed.23137.
- Carrau RL, Segas J, Nuss DW, Snyderman CH, Janecka IP, Myers EN, D'Amico F, Johnson JT. Squamous cell carcinoma of the sinonasal tract invading the orbit. *Laryngoscope*. 1999 Feb;109(2 Pt 1):230-5.
- Wu X, Tang P, Qi Y. Management of the orbital contents in radical surgery for squamous cell carcinoma of the maxillary sinus. *Chin Med J (Engl)*. 1995 Feb;108(2):123-5.
- Chu Y, Liu HG, Yu ZK. Patterns and incidence of sinonasal malignancy with orbital invasion. *Chin Med J (Engl)*. 2012 May;125(9):1638-42.
- Tiwari R, van der Wal J, van der Waal I, Snow G. Studies of the anatomy and pathology of the orbit in carcinoma of the maxillary sinus and their impact on preservation of the eye in maxillectomy. *Head Neck*. 1998 May;20(3):193-6.
- Som ML. Surgical management of carcinoma of the maxilla. *Arch Otolaryngol*. 1974 Apr;99(4):270-3.
- Essig GF, Newman SA, Levine PA. Sparing the eye in craniofacial surgery for superior nasal vault malignant neoplasms: analysis of benefit. *Arch Facial Plast Surg*. 2007 Nov-Dec;9(6):406-11.
- McCary WS, Levine PA, Cantrell RW. Preservation of the eye in the treatment of sinonasal malignant neoplasms with orbital involvement. A confirmation of the original treatise. *Arch Otolaryngol Head Neck Surg*. 1996 Jun;122(6):657-9.
- Jansen EP, Keus RB, Hilgers FJ, Haas RL, Tan IB, Bartelink H. Does the combination of radiotherapy and debulking surgery favor survival in paranasal sinus carcinoma? *Int J Radiat Oncol Biol Phys*. 2000 Aug 1;48(1):27-35.

- Nemet AY, Martin P, Bengler R, Kourt G, Sharma V, Ghabrial R, Danks J. Orbital exenteration: a 15-year study of 38 cases. *Ophthal Plast Reconstr Surg*. 2007 Nov-Dec;23(6):468-72.
- Goldberg RA, Kim JW, Shorr N. Orbital exenteration: results of an individualized approach. *Ophthal Plast Reconstr Surg*. 2003 May;19(3):229-36.
- Suarez C, Llorente JL, Fernandez De Leon R, Maseda E, Lopez A. Prognostic factors in sinonasal tumors involving the anterior skull base. *Head Neck*. 2004 Feb;26(2):136-44.
- Perry C, Levine PA, Williamson BR, Cantrell RW. Preservation of the eye in paranasal sinus cancer surgery. *Arch Otolaryngol Head Neck Surg*. 1988 Jun;114(6):632-4.
- Straub W. The first German textbook of ophthalmology "Augendienst" by G. Bartisch, 1583. *Doc Ophthalmol*. 1988 Jan-Feb;68(1-2):105-14.
- Sisson GA. Symposium: 3. Treatment of malignancies of paranasal sinuses. Discussion and summary. *Laryngoscope*. 1970 Jun;80(6):945-53.
- Conley J. The risk to the orbit in head and neck cancer. *Laryngoscope*. 1985 May;95(5):515-22.
- Karabekmez FE, Selimoglu MN, Duymaz A, Karamese MS, Keskin M, Savaci N. Management of neglected periorbital squamous cell carcinoma requiring orbital exenteration. *J Craniofac Surg*. 2014 May;25(3):729-34.
- Eisen MD, Yousem DM, Loevner LA, Thaler ER, Bilker WB, Goldberg AN. Preoperative imaging to predict orbital invasion by tumor. *Head Neck*. 2000 Aug;22(5):456-62.
- Kim HJ, Lee TH, Lee HS, Cho KS, Roh HJ. Periorbita: computed tomography and magnetic resonance imaging findings. *Am J Rhinol*. 2006 Jul-Aug;20(4):371-4.
- Dulguerov P, Jacobsen MS, Allal AS, Lehmann W, Calcaterra T. Nasal and paranasal sinus carcinoma: are we making progress? A series of 220 patients and a systematic review. *Cancer*. 2001 Dec 15;92(12):3012-29.
- Singh N, Eskander A, Huang SH, Curtin H, Bartlett E, Vescan A, Kraus D, O'Sullivan B, Gentili F, Gullane P, Yu E. Imaging and resectability issues of sinonasal tumors. *Expert Rev Anticancer Ther*. 2013 Mar;13(3):297-312.



Questions?